-
NUMBER OF INSIDER BUYING
(Last 12 Months)
0 -
NUMBER OF INSIDER SELLING
(Last 12 Months)
9 -
AMOUNT OF INSIDERS BUYING
(Last 12 Months)
$0 -
AMOUNT OF INSIDERS SELLING
(Last 12 Months)
$60.73 M
Enliven Therapeutics, Inc. Insider Transactions
Enliven Therapeutics, Inc. Insider Trades History
| Insider Name | Buy/Sell | Shares Bought/Sold @ Price |
Total Transaction | Shares Held After Transaction |
Transaction Date | Filing Date | Details |
|---|---|---|---|---|---|---|---|
|
Kintz Samuel
CEO |
Sell | 2,730 @ $27.50 | $75,075 | 1,033,793 | 10/07/2024 | 10/08/2024 | |
|
Hohl Benjamin
CHIEF FINANCIAL OFFICER |
Sell | 1,270 @ $27.51 | $34,935 | 0 | 10/07/2024 | 10/08/2024 | |
|
Lyssikatos Joseph P
CHIEF SCIENTIFIC OFFICER |
Sell | 7,522 @ $27.51 | $206,937 | 1,069,887 | 10/04/2024 | 10/08/2024 | |
|
Kintz Samuel
CEO |
Sell | 12,206 @ $27.51 | $335,792 | 1,036,523 | 10/04/2024 | 10/08/2024 | |
|
Hohl Benjamin
CHIEF FINANCIAL OFFICER |
Sell | 10,218 @ $27.51 | $281,079 | 0 | 10/04/2024 | 10/08/2024 | |
|
Heyman Richard A.
Director |
Sell | 2,825 @ $27.51 | $77,704 | 125,760 | 10/04/2024 | 10/08/2024 | |
|
Lyssikatos Joseph P
CHIEF SCIENTIFIC OFFICER |
Sell | 527 @ $27.54 | $14,512 | 1,077,409 | 10/01/2024 | 10/03/2024 | |
|
Kintz Samuel
CEO |
Sell | 526 @ $27.54 | $14,485 | 1,048,729 | 10/01/2024 | 10/03/2024 | |
|
Hohl Benjamin
CHIEF FINANCIAL OFFICER |
Sell | 521 @ $27.54 | $14,347 | 0 | 10/01/2024 | 10/03/2024 | |
|
Heyman Richard A.
Director |
Sell | 518 @ $27.54 | $14,264 | 128,585 | 10/01/2024 | 10/03/2024 | |
|
Hohl Benjamin
CHIEF FINANCIAL OFFICER |
Sell | 2,000 @ $25.33 | $50,668 | 0 | 09/30/2024 | 10/01/2024 | |
|
Hohl Benjamin
CHIEF FINANCIAL OFFICER |
Sell | 4,250 @ $24.27 | $103,161 | 0 | 09/27/2024 | 10/01/2024 | |
|
Heyman Richard A.
Director |
Sell | 1,270 @ $22.41 | $28,458 | 129,103 | 09/16/2024 | 09/18/2024 | |
|
Lyssikatos Joseph P
CHIEF SCIENTIFIC OFFICER |
Sell | 11,950 @ $22.48 | $268,687 | 1,077,986 | 08/29/2024 | 09/03/2024 | |
|
Lyssikatos Joseph P
CHIEF SCIENTIFIC OFFICER |
Sell | 50 @ $23.08 | $1,154 | 1,077,936 | 08/29/2024 | 09/03/2024 | |
|
Hohl Benjamin
CHIEF FINANCIAL OFFICER |
Sell | 4,250 @ $22.54 | $95,782 | 0 | 08/27/2024 | 08/29/2024 | |
|
Kintz Samuel
CEO |
Sell | 12,000 @ $22.89 | $274,718 | 1,049,255 | 08/26/2024 | 08/28/2024 | |
|
Heyman Richard A.
Director |
Sell | 650 @ $22.82 | $14,831 | 130,993 | 08/15/2024 | 08/19/2024 | |
|
Heyman Richard A.
Director |
Sell | 620 @ $23.70 | $14,696 | 130,373 | 08/15/2024 | 08/19/2024 | |
|
Lyssikatos Joseph P
CHIEF SCIENTIFIC OFFICER |
Sell | 3,099 @ $27.56 | $85,399 | 1,089,936 | 07/31/2024 | 08/02/2024 |
Enliven Therapeutics, Inc. Frequently Asked Questions
-
Who is on Enliven Therapeutics, Inc.'s Insider Roster?
The list of insiders at Enliven Therapeutics, Inc. includes Kintz Samuel, Hohl Benjamin, Ballal Rahul D., Lyssikatos Joseph P, Patel Anish, Collins Helen Louise, Heyman Richard A., Gupta Rishi, ORBIMED ADVISORS LLC.
-
How much insider selling is happening at Enliven Therapeutics, Inc.?
Insiders have sold a total of 2.68 M Enliven Therapeutics, Inc. shares in the last 12 months for a total of 60.73 M sold.
-
Which Enliven Therapeutics, Inc. insiders have been selling company stock?
The following insiders have sold Enliven Therapeutics, Inc. shares in the last 12 months: Kintz Samuel ($4.08 M), Hohl Benjamin ($1.70 M), Ballal Rahul D. ($1.99 M), Lyssikatos Joseph P ($4.16 M), Patel Anish ($1.97 M), Collins Helen Louise ($525,960), Heyman Richard A. ($553,674), Gupta Rishi ($22.88 M), ORBIMED ADVISORS LLC ($22.88 M),